EMEA-002781-PIP01-20

Table of contents

Key facts

Active substance
Humanised Antibody Targeting the Inducible T cell Co-Stimulatory receptor
Therapeutic area
Oncology
Decision number
P/0259/2020
PIP number
EMEA-002781-PIP01-20
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of head and neck epithelial malignant neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
GlaxoSmithKline (Ireland) Limited

E-mail: eu.paediatric-plans@gsk.com
Tel.: +44 2089903650

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating